Andere talen Sinovac Biotech Ltd.

Aandelen

SVA

AGP8696W1045

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 22-02-2019			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,47 ^USD	-0,31%		-.--%	-.--%

18/01	Alternative Liquidity Index LP, een fonds beheerd door Alternative Liquidity Capital heeft de overname van 10,04% belang in Sinovac Biotech Ltd. geannuleerd.	CI
2023	Wetenschappers zien kans op gemiste kans voor lang COVID-onderzoek in China	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sinovac - WHO releases 2024-2025 Northern Hemisphere influenza vaccine component recommendations, changes to H3N2 virus	26/02
Sinovac Amends Shareholder Rights Plan	21/02
Beijing Sinovac Zhongwei Biotechnology Co., Ltd.'s 2024 information disclosure on environmental pollution prevention and control by hazardous wastes	26/01
Le conseil d'administration de Sinovac rejette à l'unanimité une offre partielle non sollicitée	18/01
Das Board of Directors von Sinovac lehnt einstimmig ein unaufgefordert abgegebenes Teilkaufangebot ab	18/01
El Consejo de Administración de Sinovac rechaza por unanimidad una OPA parcial no solicitada	18/01
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer	18/01
Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital cancelled the acquisition of 10.04% stake in Sinovac Biotech Ltd.	18/01
Alternative Liquidity Capital Announces Offer to Purchase Common Shares in Sinovac Biotech Ltd.	11/01
Scientists see risk of lost opportunity for long COVID research in China	14/12
Sinovac - Study shows, Children aged 3-8 years old receive 2 doses of influenza vaccine for better protection	30-10-23
Sinovac Biotech Ltd - A delegation from the Indonesian Ministry of Health visited Sinovac	26-10-23
Sinovac - Sharing and co-building China Sinovac has supplied more than 1.2 billion doses of vaccines to 62 'Belt and Road' countries	23-10-23
SINOVAC rend compte des progrès réalisés dans le cadre de son essai clinique concernant l’injection anti-COVID-19 à base d’anticorps SA55	11-09-23
SINOVAC informiert über die Fortschritte bei der klinischen Studie für den Anti-COVID-19-Antikörper SA55 Injection	11-09-23
SINOVAC informa sobre el desarrollo del ensayo clínico de su Inyección SA55 de anticuerpos anti-COVID-19	11-09-23
Sinovac Biotech : Clinical trials will advance treatment of COVID-19 infection - Form 6-K	11-09-23
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection	11-09-23
Sinovac Biotech Ltd. Reports on the Clinical Trial Progress of Its Anti-Covid-19 Antibody Sa55 Injection	11-09-23
The first study on the protective effect of influenza vaccine for Chinese military personnel shows that Sinovac influenza vaccine has good immunogenicity and safety among military personnel	06-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sinovac Biotech Ltd.

Aandelen

SVA

AGP8696W1045

Andere talen

Filters